Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jul 13;7(1):233.
doi: 10.1038/s41392-022-01077-w.

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations

Zhichao Liu  1   2 , Jun Liu  2   3 , Zhigang Li  4   5
Affiliations
Comment

Chemoimmunotherapy in advanced esophageal squamous cell carcinoma: optimizing chemotherapy regimens for immunotherapy combinations

Zhichao Liu et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Forest plot analysis of overall survival and progression-free survival in advanced esophageal squamous cell carcinoma for the latest phase 3, first-line trials comparing immunotherapy or placebo in combination with chemotherapy
See this image and copyright information in PMC

Comment on

References

    1. Lu Z, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714. doi: 10.1136/bmj-2021-068714. - DOI - PMC - PubMed
    1. Liu Y, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am. J. Cancer Res. 2016;6:2345–2350. - PMC - PubMed
    1. Zhang Y, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39:1578–1593.e1578. doi: 10.1016/j.ccell.2021.09.010. - DOI - PubMed
    1. Miles D, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann. Oncol. 2021;32:994–1004. doi: 10.1016/j.annonc.2021.05.801. - DOI - PubMed
    1. Chen Z, et al. Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy. Oncogenesis. 2021;10:71. doi: 10.1038/s41389-021-00359-2. - DOI - PMC - PubMed

Publication types